medigraphic.com
ISSN 1561-302X (Print)

2022, Number 4

<< Back Next >>

Rev cubana med 2022; 61 (4)

Cardiac amyloidosis

Odriozola GA, Treviño GJ

Language: Spanish
References: 13
Page: 1-7
PDF size: 306.10 Kb.


ABSTRACT

Presentation of a clinical case in relation to a rare pathology such as cardiac amyloidosis in a patient with de novo heart failure.
A 72-year-old patient with a personal pathological history of essential arterial hypertension, who started with signs and symptoms of heart failure, underwent paraclinical and imaging studies, and findings compatible with amyloid deposits were reported, so a positive endomyocardial biopsy was performed for cardiac amyloidosis.
Cardiac amyloidosis is a rare disease. The diagnosis is made through cardiovascular signs and symptoms associated with laboratory findings, imaging studies such as echocardiography and magnetic resonance imaging, as well as tissue biopsy. Treatment is focused on the type of amyloidosis that the patient presents.


REFERENCES

  1. AuEzzeddine OF, Davies DR, Scott CG, Fayyaz AU, Askew JW, McKie PM, et al. Prevalence of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction. JAMA Cardiology. U.S. 2021 [acceso: 31/03/2022];6(11). Disponible en: https://pubmed.ncbi.nlm.nih.gov/34431962/

  2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet 2016 (London, England). U.S. National Library of Medicine. [acceso: 31/03/2022];387(10038). Disponible en: https://pubmed.ncbi.nlm.nih.gov/26719234/

  3. Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position statement on the evaluation and management of patients with cardiac amyloidosis. The Canadian journal of cardiology. U.S. National Library of Medicine. 2020 [acceso: 31/03/2022];36(3). Disponible en: https://pubmed.ncbi.nlm.nih.gov/32145862/

  4. Kyle RA, Larson DR, Kurtin PJ, Kumar S, Cerhan JR, Therneau TM, et al. Incidence of al amyloidosis in Olmsted County, Minnesota, 1990 through 2015. Clinic proceedings. U.S. National Library of Medicine. 2019 [acceso: 31/03/2022];79(7) Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6401262/

  5. Rapezzi C, Quarta CC, Obici L, Perfetto F, Longhi S, Salvi F, et al. Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively cardiac phenotype: An Italian perspective. Italian Ministry of Health. Oxford University Press. 2016 [acceso: 31/03/2022];34(7) Disponible en: https://moh-it.pure.elsevier.com/en/publications/disease-profile-and-differential-diagnosis-of-hereditary-transthy

  6. Ausdem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: Useful or harmful?. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. U.S. National Library of Medicine. 2017 [acceso: 31/03/2022];24. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28434295/

  7. Martínez Naharro A, González López E, Corovic A, Mirelis JG, Baksi A J, Moon JC, et al. High prevalence of intracardiac thrombi in cardiac amyloidosis. Journal of the American College of Cardiology. U.S. National Library of Medicine. 2019 [acceso: 31/03/2022];73(13). Disponible en: https://pubmed.ncbi.nlm.nih.gov/30947929/

  8. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, et al. Serum cardiac troponins and N-terminal pro-brain Natriuretic Peptide: A staging system for primary systemic amyloidosis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. U.S. National Library of Medicine. 2004 [acceso: 31/03/2022];15(18). Disponible en: https://pubmed.ncbi.nlm.nih.gov/15365071/

  9. Cyrille NB, Goldsmith J, Álvarez J, Maurer MS. Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. The American journal of cardiology. U.S. National Library of Medicine. 2014 [acceso: 31/03/2022];114 (7). Disponible en: https://pubmed.ncbi.nlm.nih.gov/25212550/

  10. Longhi S, Quarta CC, Milandri A, Lorenzini M, Gagliardi C, Manuzzi L, et al. Atrial fibrillation in amyloidotic cardiomyopathy: Prevalence, incidence, risk factors and prognostic role. Amyloid: the international journal of experimental and clinical investigation: the official journal of the International Society of Amyloidosis. U.S. National Library of Medicine. 2020 [acceso: 31/03/2022];6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/25997105/

  11. Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. Circulation. U.S. National Library of Medicine. 2017 [acceso: 31/03/2022]135(14) Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392416/

  12. Carvalho FP, Erthal F, Azevedo CF. The role of Cardiac Mr Imaging in the assessment of patients with cardiac amyloidosis. Magnetic resonance imaging clinics of North America. U.S. National Library of Medicine. 2019 [acceso: 31/03/2022];27(3). Disponible en: https://pubmed.ncbi.nlm.nih.gov/31279449/

  13. Nativi-Nicolau J, Maurer MS. Amyloidosis cardiomyopathy: Update in the diagnosis and treatment of the most common types. Current opinion in cardiology. U.S. National Library of Medicine. 2018 [acceso: 31/03/2022];33(5). Disponible en: https://pubmed.ncbi.nlm.nih.gov/30015648/




2020     |     www.medigraphic.com